sur ABIVAX (EPA:ABVX)
Abivax: Terms of the Annual General Meeting and outlook for 2025
Biotechnology company Abivax announced that its Annual General Meeting will be held on June 6, 2025, in Paris. This announcement comes as the company advances key milestones, including its Phase 3 ABTECT program. The trials are expected to finalize patient enrollment in the second quarter of 2025, with results expected in the third quarter.
Marc de Garidel, CEO, highlighted the importance of 2025 for Abivax, marked by its investment in 120,000 shares. This decision aims to strengthen shareholder confidence as it approaches a potential commercialization. Abivax's lead candidate, obefazimod, targets chronic inflammatory diseases and is currently in phase 3 clinical trials.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX